Gen-Probe expands Dx offering with Prodesse buy
This article was originally published in Clinica
In a bid to diversify its range of molecular tests for infectious diseases, Gen-Probe is to purchase Prodesse for $60m in cash. The deal, which is expected to close in the next month, could reach $85m if Prodesse achieves certain financial and regulatory milestones in 2010 and 2011.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals